GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Immuron IMC.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.03

-2.86%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Immuron — daily ASX:IMC

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Immuron on TradingView ↗
Market value
A$7.8m
Last close × shares
Volume
134.6k
Shares, 9 Nov 2026

About Immuron

Its shares trade on ASX under the ticker IMC.AX. It has been listed since 30 April 1999. In the fiscal year to 30 June 2026, it reported revenue of A$7.7m and a net loss of A$3.8m. At that date it held total assets of A$13.0m and shareholders' equity of A$11.0m.

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The firm has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The firm sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. The company also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The firm also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.

Figures and description from our data supplier, not checked against the company's own report.

More about Immuron →

Latest on Immuron

Our reporting

We have not reported on Immuron yet.

Next results

19 Feb 2027

Due on 19 Feb 2027. Analysts expect earnings of -0.00 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Immuron's ticker?

Immuron trades as IMC.AX on ASX, under ISIN AU000000IMC7.

What was Immuron's last closing price?

0.03 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Immuron next report results?

Results are expected on 19 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.